SARAH HAWK: Open Payments
NPI 1588632897 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 16 payments from 7 companies in 2025. Trend: 2023 $724 · 2024 $2,746 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. | 6 | $245 |
| Novo Nordisk Inc | 3 | $228 |
| Octapharma USA, Inc. | 2 | $80 |
| CSL Behring | 1 | $50 |
| PFIZER INC. | 2 | $50 |
| GENZYME CORPORATION | 1 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
Products named: Hemlibra, WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN), HEMGENIX, XYNTHA, QFITLIA, VONVENDI.
Industry payments across OK — which companies pay providers there.
